Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

About this update from Bolt Biotherapeutics, Inc.

[{"type":"image","alt":"Bolt Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Bolt Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIPaI3UaLPpJb6VD5RYb0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c","width":166,"height":74}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of $70.2 million as of December 31, 2024 anticipated to fund key milestones through mid-2026","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":353,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update. ","length":315,"tagName":"p"},{"type":"text","content":"“2024 was a transformational year for Bolt as we focused the company on efficient development of the programs that could be most impactful for patients,” said Willie Quinn, Chief Executive Officer. “BDC-4182, our next-generation ISAC, is poised to enter the clinic in the second quarter. As the only ISAC targeting the validated tumor target claudin 18.2, we believe that BDC-4182 has the potential to offer a better option for patients with stomach and other claudin 18.2-expressing cancers. We are particularly excited about BDC-4182 as validation for our Boltbody™ ISAC approach. We’ve also completed enrollment and have cleared the DLT window for the highest dose level in the BDC-3042 Phase 1 dose escalation trial and will provide a data update next quarter at a medical meeting. BDC-3042 is our first-in-c...

More updates from Bolt Biotherapeutics, Inc.